Pharmasset, Inc. is a clinical-stage pharmaceutical company focused on discovering, developing, and commercializing novel drugs to treat viral infections. The Company focuses on the development of nucleoside/tide analogs as oral therapeutics for the treatment of chronic hepatitis C virus (HCV) infection. Nucleoside/tide analogs are a class of compounds, which act as alternative substrates for the viral polymerase, thus inhibiting viral replication. The Company has three clinical-stage product candidates. It also has a series of preclinical candidates in preparation for clinical development. The three clinical product candidates include RG7128, PSI-7977 and PSI-938. In January 2012, Gilead Sciences, Inc. acquired Pharmasset, Inc.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:VRUS
CUSIPN/A
WebN/A
Phone+1-609-6134100
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding SharesN/A
Market Cap$0.00
Pharmasset (NASDAQ:VRUS) Frequently Asked Questions
What is Pharmasset's stock symbol?
Pharmasset trades on the NASDAQ under the ticker symbol "VRUS."
Has Pharmasset been receiving favorable news coverage?
Media coverage about VRUS stock has trended somewhat positive recently, Accern reports. The research firm identifies positive and negative press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Pharmasset earned a media and rumor sentiment score of 0.21 on Accern's scale. They also assigned news articles about the healthcare company an impact score of 46.23 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days. View Recent Headlines for Pharmasset.
How do I buy shares of Pharmasset?
Shares of VRUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Pharmasset?
Pharmasset's mailing address is 303A College Rd E, PRINCETON, NJ 08540-6608, United States. The healthcare company can be reached via phone at +1-609-6134100.
MarketBeat Community Rating for Pharmasset (NASDAQ VRUS)
MarketBeat's community ratings are surveys of what our community members think about Pharmasset and other stocks. Vote "Outperform" if you believe VRUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
